Healthcare Industry News: HSMN NewsFeed
News Release - May 15, 2017
Formation Biologics Announces Dosing of First Patient in a Phase I/IIa Trial of AVID100, Closing of Series B Financing, and Appointment of Dr. Anthony Tolcher to its Board of DirectorsAUSTIN, TX and MONTREAL, May 15, 2017 -- (Healthcare Sales & Marketing Network) - Formation Biologics, a clinical stage biopharmaceutical company, today announces the start of a multi-center, Phase I/IIa trial evaluating AVID100 in patients with epidermal growth factor receptor (EGFR)-expressing malignancies. The trial commenced at South Texas Accelerated Research Therapeutics in San Antonio, Texas.
Formation Biologics also announces closing of a Series B financing with HBM Healthcare Investments participating as the lead Series B investor. HBM Healthcare Investments is a global healthcare-focused investment company with net assets of approximately USD$1 billion. In addition, the investment serves as a match for the previously announced CPRIT cancer drug development grant.
The Series B supports the development of the company's two lead programs, AVID100 and AVID200, through clinical validation. AVID100 is a potent antibody-drug conjugate (ADC) targeting the EGFR. In preclinical studies, AVID100 demonstrated potent anti-tumor activity across a range of EGFR-expressing solid tumors, including those that are resistant to approved anti-EGFR therapeutics. AVID200 is an isoform-selective TGF-beta inhibitor undergoing IND-enabling development for use in orphan diseases and immune oncology.
Formation Biologics is also pleased to announce that one of the foremost clinical drug development experts, Anthony W. Tolcher M.D., FRCPC FACP, has been elected as a new member of its board of directors. Dr. Tolcher is a medical oncologist who has over 20 years of experience in drug development and clinical trials. Dr. Tolcher is also co-founder and president of START, the world's largest Phase I medical oncology program. He has been involved in many studies of new agents that subsequently were FDA-approved including pembrolizumab (Keytruda™), trastuzumab-emtansine (Kadcyla™), regorafenib (Stivarga™), liposomal vincristine (Marqibo™), cabazitaxel (Jevtana™), carfilzomib (Kyprolis™), gefitinib (Iressa™) and eribulin (HalavenTM). He completed his medical training at the the University of British Columbia and University of Toronto.
"With these achievements in place, we are well-positioned to successfully execute on our clinical development programs. I look forward to reporting on clinical progress of AVID100 and AVID200, as well as the advancement of additional candidates from our promising early-stage portfolio," commented Mr. Tikhomirov, CEO of Formation Biologics.
Source: Formation Biologics
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.